Tick saliva-derived drug shows promise in mid-stage rare skin disease study

Natalie Grover

Reporter

Scientists often lean on nature to develop drugs, for instance, the decades-old anticoagulant warfarin is derived from a chemical found naturally in sweet clover and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tick saliva-derived drug shows promise in mid-stage rare skin disease study

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Tick sali­va-de­rived drug shows promise in mid-stage rare skin dis­ease study

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Tick saliva-derived drug shows promise in mid-stage rare skin disease study